Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obrixtamig + ZL-1310 with or without atezolizumab in advanced small cell lung cancer or other neuroendocrine carcinomas
NL-OMON61682Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of obrixtamig, zocilurtatug pelitecan and atezolizumab in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC) and extrapulmonary neuroendocrine carcinoma (EPNEC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-limiting toxicities in Part 1, Treatment-emergent adverse events leading to discontinuation or dose modification in Part 2 and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
obrixtamigzocilurtatug pelitecanatezolizumab
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NL-OMON61682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61682.